Top Markets
Coin of the day
CARGO Therapeutics, Inc. Common Stock CARGO Therapeutics, Inc. Common Stock

CARGO Therapeutics, Inc. Common Stock

CRGX
Rang în acțiuni #18091
CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company... CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering innovative chimeric antigen receptor (CAR) T-cell therapies for patients battling cancer. Its primary therapeutic candidate is CRG-022, an autologous CD22 CAR T-cell product. This therapy is specifically engineered to counteract mechanisms of resistance in B-cell malignancies by targeting CD22, a distinct tumor antigen prevalent in these conditions. The company's pipeline also includes CRG-023, a novel tri-specific CAR T product candidate designed to engage tumor cells through three different B-cell antigen targets. Formerly known as Syncopation Life Sciences, Inc., the company adopted its current name, CARGO Therapeutics, Inc., in September 2022. Established in 2019, CARGO Therapeutics is headquartered in San Mateo, California.
Preț acțiune
$4.47
Ultima sincronizare: 2025-08-20
Capitalizare de piață
$213.06M
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează CARGO Therapeutics, Inc. Common Stock (CRGX)

Categorie

Venituri pentru CARGO Therapeutics, Inc. Common Stock (CRGX)
Venituri în Sep 2026 TTM: 0
Conform celor mai recente rapoarte financiare ale CARGO Therapeutics, Inc. Common Stock, venitul actual al companiei (TTM) este 0. În anul 2026, compania a avut un venit de 0 egal cu venitul din anul 2026, care a fost de 0. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru CARGO Therapeutics, Inc. Common Stock din 2026 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
Nu sunt suficiente date pentru perioada selectată.
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
$12.62B -
US
$6.02B -
NL
$2.23B -
US
$15.74B -
AU
- -
CH